Elias S. Siraj ( MD, FACP, FACE, Associate Professor of Medicine, Director of the diabetes program and Director of Clinical Endocrinology at Temple University School of Medicine) presented at Chicago ADA conference, results from a post-hoc analysis, which suggest that higher insulin doses were not responsible for the increased cardiovascular mortality found in the ACCORD trial. Main results from ACCORD demonstrated an association between increased all-cause and CV mortality in patients assigned to intensive treatment for diabetes, but several post-hoc analyses have been unable to pinpoint the cause.

Siraj reported that, consistent with prior analyses of all-cause mortality, higher HbA1c remained associated with higher CV mortality before (HR=1.38;. P<.0001) and after adjustment for baseline variables and insulin exposure (HR=1.49; P<.0001).

“In conclusion, after adjustment for covariates, insulin dose was not associated with increased CV morality, and these results do not support the hypothesis that higher dose of insulin is an independent risk factor for CV mortality,” Siraj said.

Read More